Medication-Attributable Adverse Events in Heart Failure Trials

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Initiation of guideline-directed medical therapies (GDMTs) for heart failure with reduced ejection fraction (HFrEF) is often limited by concerns about tolerability and adverse events (AEs).
• Understanding the true incidence and attribution of AEs in HFrEF patients is crucial for optimizing treatment strategies.
• This meta-analysis investigates the comparative rates of AEs between GDMTs and placebo in landmark HFrEF trials.

Approach:

• A meta-analysis was conducted on 17 landmark clinical trials for HFrEF.
• Adverse event (AE) rates were assessed for each class of GDMT in both placebo and intervention arms.
• Statistical analysis included overall AE rates, absolute differences between arms, and odds of specific AEs.

Key Points:

• Adverse events (AEs) were frequently reported (75%-85% of participants) across all GDMT classes in HFrEF trials.
• No significant difference in AE frequency was observed between GDMT intervention and placebo arms, except for ACE inhibitors (+5% absolute difference, P < 0.001).
• Discontinuation rates due to AEs did not significantly differ between intervention and placebo, with beta-blockers showing a slight decrease in discontinuation in the intervention arm (-1.1%, P = 0.015).

Conclusions:

• Adverse events (AEs) are common in clinical trials of guideline-directed medical therapies (GDMTs) for heart failure with reduced ejection fraction (HFrEF).
• The similar rates of AEs between active medication and placebo suggest that many events are attributable to the underlying severe disease state rather than specific HFrEF therapies.
• These findings support the continued use and titration of GDMTs in HFrEF, as the observed AEs do not appear to be a significant deterrent compared to placebo.